. Author manuscript; available in PMC: 2022 Jun 1.

Published in final edited form as: Eur J Cancer. 2021 Apr 21;150:83–94. doi: 10.1016/j.ejca.2021.02.042

Table 3:

Proportional hazards models of overall survival (OS) and progression free-survival (PFS) with Epic Sciences CTC count represented continuously and dichotomized at 3 CTC/mL in the Validation cohort.

		Model with Dichotomized CTC Counts (≥ 3/mL vs. <3ml)		Model with Continuous CTC Counts^*
		HR (95% CI)	P	HR (95% CI)	P
Overall Survival
	Univariate Analysis
	CTC	2.5 (1.6-3.9)		1.4 (1.2-1.6)
	Multivariable Analysis
	CTC	1.8 (1.1-3.0)	0.03	1.3 (1.1-1.6)	0.002
	prognostic risk-score ²² (continuous)	1.01 (1.00-1.02)	0.01	1.00 (0.99-1.01)	0.48
Progression Free Survival
	Univariate Analysis
	CTC	2.2 (1.4-3.3)		1.3 (1.2-1.5)
	Multivariable Analysis
	CTC	1.7 (1.1-2.9)	0.03	1.3 (1.1-1.5)	0.01
	prognostic risk-score ²² (continuous)	1.01 (1.00-1.01)	0.07	1.00 (0.99-1.01)	0.67

CTC – Circulating Tumor Cell; ALK – alkaline-phosphatase; LDH – lactate-dehydrogenase; PSA – prostate specific antigen;

log2(x+1) transformed